Publications of Johannes M. Heuckmann
All genres
Journal Article (14)
2015
Journal Article
16, 7 (2015)
Identification of novel fusion genes in lung cancer using breakpoint assembly of transcriptome sequencing data. Genome Biology
Journal Article
526 (7575), pp. 700 - 704 (2015)
Telomerase activation by genomic rearrangements in high-risk neuroblastoma. Nature
Journal Article
6 (36), pp. 38458 - 38468 (2015)
Intermittent high-dose treatment with erlotinib enhances therapeutic efficacy in EGFR-mutant lung cancer. Oncotarget 2014
Journal Article
4 (4), pp. 415 - 422 (2014)
CD74-NRG1 fusions in lung adenocarcinoma. Cancer Discovery
Journal Article
4 (2), pp. 246 - 257 (2014)
Cell-autonomous and non-cell-autonomous mechanisms of transformation by amplified FGFR1 in lung cancer. Cancer Discovery 2012
Journal Article
18 (17), pp. 4682 - 4690 (2012)
Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants. Clinical Cancer Research
Journal Article
44 (10), pp. 1104- - 11xx (2012)
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nature Genetics
Journal Article
109 (42), pp. 17034 - 17039 (2012)
A framework for identification of actionable cancer genome dependencies in small cell lung cancer. Proceedings of the National Academy of Sciences of the United States of America 2011
Journal Article
1 (1), pp. 78 - 89 (2011)
Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discovery
Journal Article
17 (23), pp. 7394 - 7401 (2011)
ALK mutations conferring differential resistance to structurally diverse ALK inhibitors. Clinical Cancer Research
Journal Article
71 (14), pp. 4920 - 4931 (2011)
Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors. Cancer Research 2010
Journal Article
70 (3), pp. 868 - 874 (2010)
Chemogenomic profiling provides insights into the limited activity of irreversible EGFR inhibitors in tumor cells expressing the T790M EGFR resistance mutation. Cancer Research
Journal Article
2 (62), p. 62ra93 - 62ra93 (2010)
Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Science Translational Medicine 2009
Journal Article
106, pp. 18351 - 18356 (2009)
Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer. Proceedings of the National Academy of Sciences of the United States of America